Myeloperoxidase enzyme and Ferric-reducing antioxidant power concentrations in lean and obese dogs

Paulo, Rodrigo Rodrigues; Galvão, Victória Elizabeth; Silva, Gustavo Gomes da; Porto, Laura Pereira; Tonossu, Juliana Mayumi; Silva, Maira Beatriz Gandolfi; Guimarães-Okamoto, Priscylla Tatiana Chalfun; Takahira, Regina Kiomi; Rahal, Sheila Canevese; Melchert, Alessandra

doi:10.1007/s11259-022-10059-w

Cited by 1 publication

(1 citation statement)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Higher serum levels of the acute phase inflammation proteins including ferritin (Franco-Martinez et al, 2023), myeloperoxidase (Paulo et al, 2023), C-reactive protein and haptoglobin (Vecchiato et al, 2023), number of neutrophils (Paulo et al, 2023) were observed in obese dogs. In humans, metformin specifically inhibits macrophage proinflammatory cytokine secretion without inhibiting their differentiation or activation (Cameron et al, 2016).…”

Section: ефективність метформіну за лікування сук із карциномою молоч...mentioning

confidence: 99%

Efficacy of metformin treatment for bitches with the mammary gland carcinoma

Bilyi,

Kovalenko

2023

TAVM

View full text Add to dashboard Cite

The relevance of improvement and clinical approval of modern treatment regimens is determined by the insufficient efficiency of protocols for the treatment of malignant tumors in dogs and the lack of research on the possibility of repurposing certain pharmacological agents for use in veterinary oncology. The manuscript demonstrates the results of a pilot study of using metformin as part of a chemotherapy protocol in female dogs with poorly differentiated tubular mammary carcinoma after mastectomy. Considering the hypoglycemic effect of metformin, it was used as part of an adjuvant protocol in a metronomic mode in female dogs with a normal and high body mass index. Combined oral administration of cyclophosphamide (endoxan) and metformin at a dose of 12.5 mg/m 2 and 10 mg/kg, respectively, for 6 months prolonged the median survival in female dogs with a normal body index (from 135.8 days, 95% CI 40-234 to 178.6 days, 95% CI 22-394, p < 0.01) as well as in overweight patients (from 93.4 days, 95% CI 15-174 to 237.8 days, 95% CI 38-373, p < 0.001). Herewith, a high body mass index compared to a normal one recognized as the risk of animal death due to the disease progression. The feasibility of using metformin in overweight patients is consistent with a reliably high glucose level before starting treatment. Herewith, blood content of triglycerides and total cholesterol did not depend on the body weight of the dogs and was within the physiological norm in all dogs. Adjuvant therapy with cyclophosphamide (endoxan) and metformin in a metronomic mode for six months was accompanied by a slight decrease (within the lower limit of reference values) of the blood glucose level against the background of the absence of pronounced changes in the concentration of triglycerides and total cholesterol. Improved long-term prognosis and the insignificant risk of side effects allow recommending metronomic therapy with cyclophosphamide (endoxan) and metformin after mastectomy in female dogs with mammary gland carcinoma.

show abstract